Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Other financing activities (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Other financing activities for 7 consecutive years, with $416000.0 as the latest value for Q4 2025.

  • Quarterly Other financing activities rose 41.98% to $416000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2025, down 5.2% year-over-year, with the annual reading at $1.5 million for FY2025, 5.2% down from the prior year.
  • Other financing activities for Q4 2025 was $416000.0 at Kymera Therapeutics, down from $419000.0 in the prior quarter.
  • The five-year high for Other financing activities was $641000.0 in Q3 2024, with the low at -$925000.0 in Q4 2023.
  • Average Other financing activities over 5 years is $256250.0, with a median of $299000.0 recorded in 2022.
  • The sharpest move saw Other financing activities skyrocketed 222.94% in 2021, then tumbled 403.28% in 2023.
  • Over 5 years, Other financing activities stood at $156000.0 in 2021, then skyrocketed by 95.51% to $305000.0 in 2022, then crashed by 403.28% to -$925000.0 in 2023, then soared by 131.68% to $293000.0 in 2024, then surged by 41.98% to $416000.0 in 2025.
  • According to Business Quant data, Other financing activities over the past three periods came in at $416000.0, $419000.0, and $382000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.